Anatomical evidence indicates that
cholinergic and opioidergic systems are co-localized and acting on the same neuron. However, the regulatory mechanisms between
cholinergic and opioidergic system have not been well characterized. In the present study, the potential involvement of
mu-opioid receptors in mediating the changes of toxic signs and
muscarinic receptor binding after administration of irreversible anti-
acetylcholinesterase diisopropylfluorophosphate (
DFP) was investigated.
DFP (1 mg/kg/day,
subcutaneous injection, s.c.)-induced
tremors and chewing movements were monitored during the 28-day treatment period in
mu-opioid receptor knockout and wild type mice. Autoradiographic studies of total, M1, and
M2 muscarinic receptors were conducted using [(3)H]-
quinuclidinyl benzilate, [(3)H]-
pirenzepine, and [(3)H]-AF-DX384 as
ligands, respectively.
DFP-induced
tremors in both
mu-opioid receptor knockout and wild type mice showed tolerance development. However,
DFP-induced
tremors in
mu-opioid receptor knockout mice showed delayed tolerance development than that of
DFP-treated wild type controls.
DFP-induced chewing movements in both
mu-opioid receptor knockout and wild type mice failed to show development of tolerance after four weeks of treatment.
M2 muscarinic receptor binding of
DFP-treated
mu-opioid receptor knockout mice was significantly decreased than that of the
DFP-treated wild type controls in the striatum, but not in the cortex and hippocampus. However, there were no significant differences in total and
M1 muscarinic receptor binding between
DFP-treated
mu-opioid receptor knockout and wild type mice in the cortex, striatum and hippocampus. These studies indicate that
mu-opioid receptors play an important role through the striatal
M2 muscarinic receptors to regulate the development of tolerance to
DFP-induced
tremors.